Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Diagnosed with Parkinson's disease (PD) within a maximum of 3 years prior to Screening.~* Score of ≤2.5 on the Modified Hoehn and Yahr Scale.~* Has not received any medication for the treatment of the motor symptoms of PD for at least 12 weeks prior to Day 1 and, in the opinion of the Investigator, is not expected to require PD treatment for at least 6 months following Day 1. Maximum total duration of prior PD regimens should not exceed 30 days. Stable (at least 8 weeks) dosages of medications that are used to treat conditions other than PD tremor are allowed. Further guidance will be provided by the study's Medical Monitor on a case by case basis.~* Screening dopamine transporter (DaT)/ single-photon emission computed tomography (SPECT) results consistent with neurodegenerative Parkinsonism (central reading).~* All women of childbearing potential and all men must practice highly effective contraception during the study and for 6 months after their last dose of study treatment.~Exclusion Criteria:~* Presence of freezing of gait.~* Montreal cognitive assessment (MOCA) score \<23 or other significant cognitive impairment or clinical dementia that, in the opinion of the Investigator, would interfere with study evaluation.~* History of or screening brain magnetic resonance imaging (MRI) scan indicative of clinically significant abnormality, as read by central reader.~* History of severe allergic or anaphylactic reactions, or history of hypersensitivity to BIIB054 or any of the inactive ingredients in the drug product or to radioligands or iodine used in the study.~* Participation in any active immunotherapy study targeting alpha-synuclein.~* Use of allowed medications not previously specified at doses that have not been stable for at least 8 weeks before Day 1, and/or that are not expected to remain stable for the duration of the study.~* Clinically significant abnormal laboratory test values at Screening, as determined by the Investigator.~* Blood donation (1 unit or more) within 8 weeks before Day 1 (must also refrain from donating blood for the duration of the study).~NOTE : Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.~Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks.
- BIIB054 250 mg (Type: EXPERIMENTAL): Participants will receive BIIB054 250 milligrams (mg) intravenous (IV) infusion on Day 1 and then every 4 weeks.
- BIIB054 1250 mg (Type: EXPERIMENTAL): Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
- BIIB054 3500 mg (Type: EXPERIMENTAL): Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy